What Fasenra treats.
- Severe eosinophilic asthma
- Eosinophilic granulomatosis with polyangiitis (EGPA)
The mechanism.
Fasenra (benralizumab) targets the IL-5 receptor on eosinophils — white blood cells that drive inflammation in eosinophilic asthma — and triggers their direct depletion. This near-complete reduction of eosinophils helps reduce asthma exacerbations and oral steroid use.
Your Fasenra infusion experience.
Fasenra is given as a 1-hour subcutaneous-or-IV administration. After three loading doses (4 weeks apart), maintenance is every 8 weeks. Many patients see meaningful improvement in asthma control within 4 to 6 months.
Insurance & out-of-pocket cost.
Fasenra is covered by most commercial insurance and Medicare Part B when prescribed by your physician for an FDA-approved indication. We verify your benefits before your first infusion and handle prior authorization on your behalf. Most commercially insured patients pay only their standard specialty copay — typically $20–$100 per visit. Manufacturer copay assistance programs may further reduce your cost.